Sara Centuori

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).”.

Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6015

N/A

0.312DataRank · unranked

7 citations

Nabil F. Saba, Denise J. Roe, Jessica R. Bauman, John M. Kaczmar, Aarti Bhatia +14 more

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.249

N/A

0DataRank · unranked

2 citations

Peter A. Pinto, Howard L. Parnes, Christian P. Pavlovich, Edward Uchio, Mike Nguyen +13 more